What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing by Eli Lilly & Company is to officially announce and furnish their financial results for the second quarter ended June 30, 2023, through an attached press release.

Where can I find the detailed financial results?

The detailed financial results and operational performance are provided in the press release dated August 8, 2023, which is attached as Exhibit 99.1 to this 8-K filing.

Is the information in this 8-K considered 'filed' for all purposes?

No, the information furnished in Item 2.02 of this 8-K, including the attached press release, is being furnished and is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless specifically incorporated by reference into another filing.

What should investors pay close attention to in the accompanying press release?

Investors should focus on key financial metrics like revenue, earnings per share, and profit margins. Additionally, they should look for performance details of major products, updates on the drug pipeline, and any revised financial guidance provided by Eli Lilly for the remainder of the fiscal year.

LLY 8-K: Earnings & Results

Summary

Eli Lilly & Company (LLY) filed an 8-K on August 8, 2023, primarily to furnish its second-quarter 2023 financial results. The press release, attached as Exhibit 99.1, details the company's performance for the quarter ended June 30, 2023. While the filing itself is procedural, the attached press release contains the substantive financial and operational data that investors will scrutinize. Investors should focus on the details within the press release for insights into revenue growth, profitability, key product performance (especially in areas like diabetes and obesity), and any forward-looking guidance provided by the company. This 8-K serves as the official notification of the release of this crucial financial information, marking a point for market analysis of Lilly's recent performance and future outlook.

Key Highlights

18-K filing on August 8, 2023, confirms the release of Q2 2023 financial results.
2The core information is contained within the attached press release (Exhibit 99.1).
3The filing itself does not contain new financial data but references the official earnings announcement.
4Focus for investors should be on the details presented in the August 8, 2023 press release.
5This report is a procedural notification of financial results disclosure.
6The information is furnished, not deemed 'filed' for certain regulatory purposes.
7Includes the Cover Page Interactive Data File as Exhibit 104.

ELI LILLY & Co 8-K Report, Financial Results (Aug 8, 2023)

Summary

Key Highlights

Frequently Asked Questions